Drug Solutions Podcast: Examining the State of Biopharma Investment
In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.
In this episode of the Drug Solutions podcast, Grant Playter, Associate Editor, speaks with Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023. Topics of discussion include key areas of investment, where investment is occurring and why, and how the industry is adjusting to post-COVID regulatory and supply chain changes.
About the Speaker
Dr. Siegfried Schmitt is a Fellow of the Royal Society of Chemistry, Chartered Chemist and Chartered Scientist. He started his career with F.Hoffmann-La Roche in Basel, Switzerland, where he worked as Senior Production Chemist in Active Pharmaceutical Ingredients and Vitamin production. Following a move to the UK, he worked for several years as consultant and validation manager for Raytheon E&C, followed by two years with ABB Eutech as Senior Lead Consultant. In 2002 Dr Schmitt joined Amersham Health (now GE Healthcare) as global Quality Assurance Director in Information Management. In July 2007 he joined PAREXEL Consulting in the UK as Principal Consultant. Dr Schmitt regularly publishes articles on scientific and business subjects, and has written several books. He speaks on a variety of topics at international conferences and industry meetings.
About the Drug Solutions Podcast
Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
